Presented by Heather Hydzik, ND | February 4, 2026 at 12 PM Pacific

The hypothalamic-pituitary-adrenal (HPA) axis coordinates stress regulation-but it doesn't act alone. Neurotransmitters shape the stress response and gut health is essential for HPA axis vitality. Join us as we explore the physiological mechanisms that govern HPA axis function, the role of neurotransmitters and digestive health, as well as the latest advancements in assessment tools. By the end of this session, you'll have a well-rounded approach to optimizing adrenal function-leveraging neurotransmitter balance, gut health, and targeted testing to enhance patient care. Don't miss this opportunity to elevate your clinical expertise.

Learning Objectives:

• Explore adrenal anatomy, physiology, and the key mechanisms that regulate a healthy HPA axis.
• Explore how the HPA axis adapts to stress and learn to identify key dysfunction patterns at different stages.
• Interpret advanced assessment tools, including diurnal cortisol patterns and the cortisol awakening response (CAR).
• Discover how neurotransmitters and gastrointestinal health influence stress tolerance and HPA axis balance.
• Implement proven strategies to rebalance the HPA axis and strengthen patient resilience to stress.

Presented by Dr. Brandon Lundell, DC, APC, DABCI, IFMCP, Dip. Ac., NE, CAC | February 18, 2026 at 11 AM Pacific

GI assessment is foundational to functional medicine-because the gut is connected to every health and disease metric. Autoimmune disease, hormonal imbalances, neurological conditions, metabolic dysfunction-all roads lead back to the gut. But with multiple stool testing options available, knowing which test to order and when is critical. Ordering the wrong test wastes time and money. Worse, unreliable results lead to chasing ghosts-treating findings that aren't clinically relevant while missing what actually matters.

This one-hour webinar gives practitioners a clear framework for navigating the Doctor's Data GI test menu. Dr. Brandon Lundell draws from 20 years of clinical experience and having trained thousands of practitioners how to break down the GI 360, CSAP, and when to use the protocols that fit each presentation. You'll learn the technology behind each test-multiplex PCR, MALDI-TOF, culture-based methods-and more importantly, when each test is the right clinical choice. Dr. Lundell will walk through interpretation highlights including the dysbiosis index, commensal microbiome analysis, antimicrobial susceptibility testing, and stool chemistries. Whether you're new to functional GI testing or looking to sharpen your clinical decision-making, this webinar delivers practical, immediately applicable guidance.

Upon completion, participants will be able to:

• Understand the differences and applications of the entire DDI GI test suite
• Interpret the dysbiosis index, commensal microbiome analysis, and antimicrobial susceptibility results to guide treatment decisions
• Understand when a finding is clinically actionable to avoid unnecessary treatment
• Utilize stool chemistry markers to assess and support digestive function, inflammation, and immune response
• Develop targeted treatment protocols for dysbiosis, pathogen overgrowth, c. diff, and intestinal permeability based on test findings
• Determine appropriate follow-up testing strategies to monitor treatment efficacy and patient progress

Presented by Ruth Hobson, ND | March 4, 2026 at 12 PM Pacific

Hormone and metabolite testing offers powerful clinical insight, but for many practitioners, the reports can feel overwhelming and time consuming to interpret. When clinical days are full, translating complex hormone data into clear, confident treatment decisions can be a challenge.

Join Dr. Ruth Hobson for a practical, clinician focused walkthrough of the HuMap™, designed to help integrative practitioners quickly make sense of hormone metabolism without getting lost in the data. This concise webinar will focus on the four key hormone pathways; progesterones, corticoids, androgens, and estrogens, showing you how to identify clinically meaningful patterns that inform treatment decisions in real time.

You'll learn how to efficiently interpret hormone metabolism, recognize patterns linked to common concerns such as PCOS, metabolic dysfunction, sexual health issues, breast and prostate health, and optimize both endogenous and exogenous hormone strategies. This session emphasizes clinical efficiency, decision-making confidence, and actionable takeaways you can apply immediately making hormone testing a tool that works for your practice, even on your busiest days.

Learning Objectives:

• Evaluate the structure and key components of the HuMap™ report to extract clinically actionable insights for individualized patient management.
• Interpret hormone metabolism patterns identified by HuMap™ and their clinical relevance to endocrine-related conditions, including breast and prostate health, PCOS, metabolic dysfunction, etc.
• Assess the metabolism and bioavailability of exogenous hormones using HuMap™ testing to optimize the efficacy, tolerability, and safety of bioidentical hormone therapies.
• Apply evidence informed strategies to modulate enzymatic activity and optimize hormone metabolism for improved outcomes and risk reduction.

Presented by Melody Hartzler, PharmD | March 11, 2026 at 12 PM Pacific

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, yet traditional lipid panels frequently fail to capture key drivers of cardiometabolic risk. This case-based, evidence-anchored session equips clinicians with practical strategies to interpret and act on the Doctor's Data Cardiometabolic Profile, integrating traditional lipid markers with advanced biomarkers of glycemic control, insulin resistance, inflammation, oxidative stress, adipose signaling, renal function, and lipoprotein physiology.

Through real-world patient cases, participants will learn how to interpret markers including Apolipoproteins A1 and B, small dense LDL, oxidized LDL, PLAC® (Lp-PLA₂ activity), Lipoprotein(a), hs-CRP, homocysteine, insulin, glucose, 1,5-anhydroglucitol (1,5-AG), leptin, adiponectin, the leptin-to-adiponectin ratio, cystatin C, creatinine/eGFR, and comprehensive cholesterol fractions to uncover cardiometabolic risk that extends beyond LDL-centric models.

The session emphasizes pattern recognition and protocol-driven care, translating biomarker abnormalities into targeted lifestyle, nutraceutical, and-when appropriate-pharmacologic strategies aimed at improving metabolic flexibility, vascular health, and long-term cardiovascular outcomes.

Upon completion, participants will be able to:

• Describe the clinical relevance of advanced cardiometabolic biomarkers, including apolipoproteins (A1 and B), small dense LDL, oxidized LDL, PLAC® activity, Lipoprotein(a), inflammatory markers (hs-CRP, homocysteine), glycemic and insulin resistance markers (glucose, insulin, 1,5-AG), adipokines (leptin, adiponectin, leptin-to-adiponectin ratio), and renal markers (cystatin C, creatinine/eGFR), and how they complement traditional lipid testing.
• Interpret real patient case data from the Doctor's Data Cardiometabolic Risk Profile to identify patterns consistent with atherogenic dyslipidemia, metabolic dysfunction, adipose signaling imbalance, oxidative stress, and systemic inflammation.
• Apply evidence-based interventions tailored to specific biomarker abnormalities, including lifestyle and nutrition protocols, physical activity strategies, weight management approaches, targeted supplementation, and appropriate medication considerations when indicated.
• Construct individualized cardiometabolic care plans that integrate advanced biomarker findings with traditional lipid values and established cardiovascular risk frameworks to more precisely assess and mitigate patient risk.